keyword
MENU ▼
Read by QxMD icon Read
search

Crohn's and TNF

keyword
https://www.readbyqxmd.com/read/29682686/resolution-of-metastatic-colon-cancer-upon-withdrawal-of-anti-tnf-therapy-for-crohn-s-disease
#1
Bradley Wiksyk, Howard Joe, David Fenton, James K Kelly, Pauline T Truong
No abstract text is available yet for this article.
April 23, 2018: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/29676289/natural-history-and-outcome-of-inflammatory-bowel-diseases-in-children-in-saudi-arabia-a-single-center-experience
#2
Khalid M Alreheili, Khalid A Alsaleem, Ali I Almehaidib
Background/Aim: Inflammatory bowel disease (IBD) is a chronic gastrointestinal disorder which includes ulcerative colitis (UC), Crohn's disease (CD), and indeterminate colitis (IC). The natural history of pediatric IBDs is poorly understood and generally unpredictable. We aim to study the natural history of IBD in Saudi children including the extraintestinal manifestations, changes in diagnosis, disease behavior, medical management, and surgical outcome. Patients and Methods: A retrospective review of all the charts of children less than 14 years of age who were diagnosed as IBD and followed up in King Faisal Specialist Hospital and Research Center (KFSH and RC) from January 2001 to December 2011 was performed...
April 18, 2018: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/29673053/vedolizumab-as-a-rescue-therapy-for-patients-with-medically-refractory-crohn-s-disease
#3
Kristen T Crowell, Andrew Tinsley, Emmanuelle D Williams, Matthew D Coates, Anne Bobb, Walter A Koltun, Evangelos Messaris
AIM: Vedolizumab, a monoclonal antibody resulting in gut-selective anti-inflammatory activity, was FDA-approved in 2014 for use in patients with Crohn's disease (CD). The aim of the study was to investigate the efficacy of vedolizumab as a rescue therapy when other medical therapies have failed. METHOD: A retrospective review was performed on consecutive CD patients receiving vedolizumab between May 2014 and March 2016 at the Penn State Hershey IBD Center. These patients were unresponsive or intolerant to TNF antagonist therapy, and previously would have been surgical candidates...
April 19, 2018: Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland
https://www.readbyqxmd.com/read/29670622/immune-reconstitution-after-autologous-hematopoietic-stem-cell-transplantation-in-crohn-s-disease-current-status-and-future-directions-a-review-on-behalf-of-the-ebmt-autoimmune-diseases-working-party-and-the-autologous-stem-cell-transplantation-in-refractory
#4
REVIEW
Alan Graham Pockley, James O Lindsay, Gemma A Foulds, Sergio Rutella, John G Gribben, Tobias Alexander, John A Snowden
Patients with treatment refractory Crohn's disease (CD) suffer debilitating symptoms, poor quality of life, and reduced work productivity. Surgery to resect inflamed and fibrotic intestine may mandate creation of a stoma and is often declined by patients. Such patients continue to be exposed to medical therapy that is ineffective, often expensive and still associated with a burden of adverse effects. Over the last two decades, autologous hematopoietic stem cell transplantation (auto-HSCT) has emerged as a promising treatment option for patients with severe autoimmune diseases (ADs)...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29668916/extraintestinal-manifestations-in-vedolizumab-and-anti-tnf-treated-patients-with-inflammatory-bowel-disease
#5
Marla C Dubinsky, Raymond K Cross, William J Sandborn, Millie Long, Xue Song, Nianwen Shi, Yao Ding, Samantha Eichner, Brandee Pappalardo, Arijit Ganguli, Anthony Wang
Background: Extra-intestinal manifestations (EIMs) can impact morbidity in patients with inflammatory bowel diseases (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). This study compared incidence rates of EIMs in patients with moderate to severe IBD receiving gut-selective vedolizumab (VDZ) vs those receiving systemic anti-tumor necrosis factor (anti-TNF) therapies. Methods: Adult IBD patients receiving VDZ or anti-TNFs were identified from the MarketScan claims database from September 28, 2012, through September 30, 2016...
April 13, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29668901/combining-anti-tnf-%C3%AE-and-vedolizumab-in-the-treatment-of-inflammatory-bowel-disease-a-case-series
#6
Lydia C T Buer, Marte L Høivik, David J Warren, Asle W Medhus, Bjørn A Moum
Background: Anti-tumor necrosis factor α (anti-TNF-α) is important in the treatment of inflammatory bowel disease, but some patients experience only a partial response. In these patients, a combination of anti-TNF-α and vedolizumab (VDZ) may act as a bridge until the full VDZ effect occurs. At present, clinical data on combination treatment with anti-TNF-α and VDZ are not available. The aim of this case series was to evaluate the safety and clinical response of combination therapy with anti-TNF-α and VDZ in clinical practice...
April 12, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29668128/tuberculosis-associated-with-tumor-necrosis-factor-%C3%AE-antagonists-case-description-and-analysis-of-reported-cases-in-colombia
#7
Leandro Galvis, Ángel Y Sánchez, Leonardo F Jurado, Martha I Murcia
Tumor necrosis factor-α (TNF-α) is an important fundamental cytokine during the immune response against cancer and infections such as tuberculosis. This molecule also plays a key pathogenic role in complex and difficult-to-treat diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis and ulcerative colitis. The treatment of these diseases frequently needs TNF-α antagonists, which has been related to an increased risk of developing tuberculosis, mycoses, and other severe infections...
March 15, 2018: Biomédica: Revista del Instituto Nacional de Salud
https://www.readbyqxmd.com/read/29667146/cost-effectiveness-analysis-of-crohn-s-disease-treatment-with-vedolizumab-and-ustekinumab-after-failure-of-tumor-necrosis-factor-%C3%AE-antagonist
#8
Przemysław Holko, Paweł Kawalec, Andrzej Pilc
OBJECTIVE: The aim was to evaluate the cost-effectiveness of Crohn's disease (CD) treatment with vedolizumab and ustekinumab after failure of therapy with tumor necrosis factor-α antagonists (anti-TNFs). METHODS: The Markov model incorporated the lifetime horizon, synthesis-based estimates of biologics' efficacy in relation to anti-TNF exposure, and administration of biologics reflecting clinical practice (e.g., sequence of biologics, retreatment, 12-month treatment)...
April 17, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29666076/histoplasma-meets-crohn-s-disease-a-rare-case-of-new-onset-ascites
#9
Charles Robert Bosshardt, John Gnann, Nilesh Lodhia
A 53-year-old man with Crohn's disease treated with adalimumab was hospitalised with abdominal pain, fatigue, fever and chills. CT scan of the abdomen showed chronic thickening of the terminal ileum and cecum and new-onset ascites. Further studies revealed weakly positive urine and serum histoplasma antigen. Laparoscopy revealed metastatic caking of the omentum and abdominal wall; peritoneal biopsy demonstrated organisms morphologically consistent with Histoplasma capsulatum No dissemination outside of the peritoneal cavity was evident...
April 17, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29657833/paradoxical-arthritis-occurring-during-anti-tnf-in-patients-with-inflammatory-bowel-disease-histological-and-immunological-features-of-a-complex-synovitis
#10
Stefano Alivernini, Daniela Pugliese, Barbara Tolusso, Laura Bui, Luca Petricca, Luisa Guidi, Luisa Mirone, Gian Ludovico Rapaccini, Francesco Federico, Gianfranco Ferraccioli, Alessandro Armuzzi, Elisa Gremese
Objective: Paradoxical arthritis under tumour necrosis factor inhibitor (TNF-i) for inflammatory bowel disease (IBD) has been described. This study aims to evaluate the histological features of paired synovial tissue (ST) and colonic mucosa (CM) tissue in patients with IBD developing paradoxical arthritis under TNF-i. Methods: Patients with IBD without history of coexisting joint involvement who developed arthritis under TNF-i were enrolled. Each patient underwent ST biopsy and ileocolonoscopy with CM biopsies...
2018: RMD Open
https://www.readbyqxmd.com/read/29655972/effectiveness-and-safety-of-anti-tnf-therapy-for-inflammatory-bowel-disease-in-liver-transplant-recipients-for-primary-sclerosing-cholangitis-a-nationwide-case-series
#11
Romain Altwegg, Roman Combes, David Laharie, Victor De Ledinghen, Sylvie Radenne, Filomena Conti, Olivier Chazouilleres, Christophe Duvoux, Jérôme Dumortier, Vincent Leroy, Xavier Treton, François Durand, Sébastien Dharancy, Maria Nachury, Félix Goutorbe, Géraldine Lamblin, Lucile Boivineau, Laurent Peyrin-Biroulet, Georges-Philippe Pageaux
BACKGROUND: There is a lack of consensus regarding the treatment of inflammatory bowel disease (IBD) after liver transplantation (LT) forprimary sclerosing cholangitis (PSC). AIM: To investigate the safety and effectiveness of anti-TNF therapy in patients with IBD after a LT for PSC. METHODS: We reviewed the medical files of all of the IBD patients who underwent a LT for PSC and who were treated with anti-TNF therapy at 23 French liver transplantation centers between 1989 and 2012...
March 13, 2018: Digestive and Liver Disease
https://www.readbyqxmd.com/read/29627390/sodium-butyrate-inhibits-inflammation-and-maintains-epithelium-barrier-integrity-in-a-tnbs-induced-inflammatory-bowel-disease-mice-model
#12
Guangxin Chen, Xin Ran, Bai Li, Yuhang Li, Dewei He, Bingxu Huang, Shoupeng Fu, Juxiong Liu, Wei Wang
G Protein Coupled Receptor 109A (GPR109A), which belongs to the G protein coupled receptor family, can be activated by niacin, butyrate, and β-hydroxybutyric acid. Here, we assessed the anti-inflammatory activity of sodium butyrate (SB) on 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis mice, an experimental model that resembles Crohn's disease, and explored the potential mechanism of SB in inflammatory bowel disease (IBD). In vivo, experimental GPR109a-/- and wild-type (WT) mice were administered SB (5g/L) in their drinking water for 6weeks...
March 28, 2018: EBioMedicine
https://www.readbyqxmd.com/read/29625924/crohn-s-disease-treatment-practices-in-france-in1999-2013-a-prospective-survey-in-non-academic-hospitals
#13
Stéphane Nahon, Pierre Lahmek, Gilles Macaigne, Bruno Lesgourgues, Thierry Paupard
AIMS: To describe the characteristics of patients with Crohn's disease (CD) in non-academic hospitals in France and to evaluate how therapeutic practices changed between 1999 and 2013. METHODS: During 2 weeks in September 2013, we solicited disease and treatment information for CD patients seen by gastroenterologists in 57 French non-academic hospitals. In four groups of patients defined according to the date of CD diagnosis (<1999, 1999-2003, 2004-2008, and 2009-2013), the use of immunosuppressor (IS) and anti-TNF treatments during the first 5 years following diagnosis of CD was compared using the Kaplan-Meier method...
April 3, 2018: Clinics and Research in Hepatology and Gastroenterology
https://www.readbyqxmd.com/read/29623679/pregnancy-outcomes-after-exposure-to-certolizumab-pegol-updated-results-from-a-pharmacovigilance-safety-database
#14
Megan E B Clowse, Angela E Scheuerle, Christina Chambers, Anita Afzali, Alexa B Kimball, John J Cush, Maureen Cooney, Laura Shaughnessy, Mark Vanderkelen, Frauke Förger
BACKGROUND: Anti-tumor necrosis factor medications (anti-TNFs) are effective in controlling chronic inflammatory diseases, but information about their use and safety in pregnancy is limited. Consequently, anti-TNFs are often discontinued early in gestation. Certolizumab pegol (CZP), a PEGylated, Fc-free anti-TNF approved for treatment of rheumatic diseases and/or Crohn's disease, has minimal to no active placental transfer. This project provides information on pregnancy outcomes in women receiving CZP, especially those with early pregnancy exposure...
April 5, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29623442/therapeutic-drug-monitoring-in-pediatric-inflammatory-bowel-disease
#15
REVIEW
Nicholas Carman, David R Mack, Eric I Benchimol
PURPOSE OF REVIEW: Therapeutic drug monitoring (TDM) has emerged as a useful tool to optimize the use of drug therapies in adults with inflammatory bowel disease (IBD), including both Crohn's disease (CD) and ulcerative colitis (UC), especially during the use of biological therapies, for which the pharmacokinetics and pharmacodynamics are highly variable among patients. Fewer data exist in children. This review examines the current literature on TDM in pediatric IBD. RECENT FINDINGS: Drug clearance is affected by a number of patient and disease factors...
April 5, 2018: Current Gastroenterology Reports
https://www.readbyqxmd.com/read/29606936/vedolizumab-as-a-potential-culprit-in-the-development-of-ovarian-teratoma
#16
Judy A Trieu, Mohammad Bilal, Gurinder Luthra
Vedolizumab is a new humanized monoclonal antibody that has been reserved for those with moderate-to-severe Crohn's disease and ulcerative colitis who have failed immunomodulator and TNF-α antagonist therapy, and for those who have an increased risk for developing progressive multifocal leukoencephalopathy. Because it targets gastrointestinal tract-specific lymphocytes, meta-analyses and integrated studies have shown that vedolizumab causes fewer extraintestinal adverse effects, such as opportunistic infections and malignancies, compared with anti-TNF therapies...
September 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/29588183/hla-g-is-expressed-in-intestinal-samples-of-ulcerative-colitis-and-crohn-s-disease-patients-and-hla-g5-expression-is-differentially-correlated-with-tnf-and-il-10-cytokine-expression
#17
Renan Garcia Gomes, Carlos Alexandre Antunes de Brito, Valéria Ferreira Martinelli, Rossana Nascimento Dos Santos, Fabiana Oliveira Dos Santos Gomes, Christina Alves Peixoto, Janaína Oliveira Crispim, George Tadeu Nunes Diniz, Eduardo Antônio Donadi, Norma Lucena-Silva
HLA-G is an immunomodulatory molecule that can be produced by epithelial cells. Considering that TNF and IL-10 participate in bowel inflammatory disorders and that both cytokines modulate HLA-G, we evaluated HLA-G, TNF and IL-10 mRNA expression by qPCR and HLA-G protein levels by immunohistochemistry in two intestinal samples exhibiting different degree of inflammation within a patient suffering from Crohn's disease (CD) or ulcerative colitis (UC). Tissue HLA-G5 (P<0.0001), TNF (P=0.0004) and IL-10 (P=0...
March 24, 2018: Human Immunology
https://www.readbyqxmd.com/read/29579869/efficacy-and-safety-of-anti-tnf-%C3%AE-agents-in-inflammatory-bowel-disease-after-liver-transplant-a-case-series
#18
R V Olmedo-Martín, V Amo-Trillo, R González-Grande, E Tenorio-González, O Sánchez-García, J de la Cruz-Lombardo, J M Rodrigo-López, M Jiménez-Pérez
BACKGROUND: Ulcerative colitis (UC) and Crohn disease (CD) can appear de novo or worsen after liver transplant. Our aim was to assess the efficacy and safety of anti-tumor necrosis-alpha (anti-TNF-α) agents after transplantation. METHODS: We reviewed the clinical database of our center searching for all liver transplant patients with inflammatory bowel disease who were treated with anti-TNF-α agents between 1997 and 2017. Clinical response was assessed from clinical activity indices 12 weeks after starting treatment...
March 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29576767/comparison-of-concomitant-mesalamine-and-immunomodulator-therapy-and-immunomodulator-monotherapy-for-crohn-s-disease
#19
Min Seob Kwak, Kyung-Jo Kim, Jae Hee Cheon, Wan Soo Kim, Jeong-Mi Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
Background: Although immunomodulators are increasingly used in Crohn's disease (CD), a significant number of gastroenterologists still use 5-aminosalicylate (5-ASA) in combination with azathioprine (AZA) or 6-mercaptopurine (6-MP); there is limited evidence regarding the benefit of concomitant 5-ASA with AZA/6-MP compared with AZA/6-MP monotherapy for the treatment of CD. Study Design: A total of 106 patients who received AZA/6-MP for more than 3 months between January 1991 and May 2014 were identified retrospectively...
2018: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/29575262/structural-basis-for-tumor-necrosis-factor-blockade-with-the-therapeutic-antibody-golimumab
#20
Masatsugu Ono, Shoichiro Horita, Yumi Sato, Yayoi Nomura, So Iwata, Norimichi Nomura
Tumor necrosis factor α (TNFα) is a proinflammatory cytokine, and elevated levels of TNFα in serum are associated with various autoimmune diseases, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn's disease (CD), psoriasis and systemic lupus erythaematosus. TNFα performs its pleiotropic functions by binding to two structurally distinct transmembrane receptors, TNF receptor (TNFR) 1 and TNFR2. Antibody-based therapeutic strategies that block excessive TNFα signaling have been shown to be effective in suppressing such harmful inflammatory conditions...
March 25, 2018: Protein Science: a Publication of the Protein Society
keyword
keyword
24145
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"